Kalaris Therapeutics, Inc. Cash Flow-to-Debt Ratio
Kalaris Therapeutics, Inc. cash flow-to-debt ratio. Kalaris Therapeutics, Inc. (KLRS) has a Cash Flow-to-Debt Ratio of -0.32x as of March 2026, meaning its operating cash flow of $-13.35 Million could theoretically repay 0% of its total liabilities ($41.25 Million) in one year. See Kalaris Therapeutics, Inc. (KLRS) financial flexibility to measure the company's free cash flow as a share of total liabilities.
CF-to-Debt Ratio
Operating Cash Flow
Total Liabilities
Data as of
Cash Flow-to-Debt Ratio of Kalaris Therapeutics, Inc. (2018–2025)
Cash flow-to-debt ratio of Kalaris Therapeutics, Inc. from 2018 to 2025. Historical debt coverage capacity for Kalaris Therapeutics, Inc. across 8 annual periods. Check Kalaris Therapeutics, Inc. (KLRS) reinvestment rate to assess the company's total reinvestment commitment from operating cash flow.
Kalaris Therapeutics, Inc. Cash Flow-to-Debt Ratio by Year (2018–2025)
Kalaris Therapeutics, Inc. cash flow-to-debt ratio by year from 2018 to 2025. Year-by-year debt coverage analysis for Kalaris Therapeutics, Inc.. For the full cash flow conversion analysis, see cash efficiency ratio of Kalaris Therapeutics, Inc..
| Year | CF-to-Debt Ratio | Operating CF (USD) | Total Liabilities | YoY Change |
|---|---|---|---|---|
| 2025 | -1.00x | $-42.98 Million | $42.92 Million | ▲ +92.3% |
| 2024 | -12.92x | $-67.70 Million | $5.24 Million | ▼ -4321.5% |
| 2023 | -0.29x | $-14.13 Million | $48.35 Million | ▼ -2.1% |
| 2022 | -0.29x | $-9.78 Million | $34.17 Million | ▲ +83.5% |
| 2021 | -1.73x | $-106.32 Million | $61.33 Million | ▲ +49.4% |
| 2020 | -3.42x | $-60.81 Million | $17.76 Million | ▼ -202.4% |
| 2019 | -1.13x | $-20.16 Million | $17.80 Million | ▼ -317.8% |
| 2018 | 0.52x | $1.94 Million | $3.74 Million | — |